GPCRStructure Therapeutics Inc.

Healthcare
$25.51+8.2% 1Y

Price

+8.2%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 1% of companies
1/100
Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for GPCR today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (“GPCRs”). These important receptors regulate numerous and diverse physiological and pathological processes.

In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR

P/En/a
Market value$3.43B
1 year+8.2%
5 yearsn/a

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Nov 5, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Sep 8, 2026ACCG-2671 (Oral Small Molecule DACRA): Phase 1 SAD Topline Clinical Trial Results On September 8, 2026, the Company reported positive topline data for ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist (DACRA), from the SAD portion of the Phase 1/2a clinical trial.Regulation FD disclosure · Form 8-K
  2. Aug 6, 2026Structure Therapeutics Reports Second Quarter.Earnings release · press release
  3. May 7, 2026On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”) …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

Biotechnology

Ranks #194 of 196 by RyuScore

Compare peers
DYN+1.7%
Dyne Therapeutics, Inc.
QURE+0.22%
uniQure N.V.
BEAM+4.6%
Beam Therapeutics Inc.
IDYA+0.21%
IDEAYA Biosciences, Inc.
ELVN+0.94%
Enliven Therapeutics, Inc.
ARQT+8.5%
Arcutis Biotherapeutics, Inc.